IL-2 R alpha

IL-2 R alpha

IL-2 R alpha 詳細

Molecule Name
Interleukin-2 receptor alpha chain
分子の別称
IL2RA,CD25,p55,IL2-RA,IL-2-RA
Drug Development Progress
治験薬の数16
市販薬剤の数3
研究&開発段階Approved
ターゲットの別称
TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,Insulin-Dependent Diabetes Mellitus 10,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,Interleukin-2 Receptor alpha Subunit,IL-2R alpha
バックグランド
Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

IL-2 R alpha 製品リスト

Species
  • Human(5)
  • Cynomolgus(2)
  • Mouse(2)
  • Canine(1)
  • Rat(1)
  • Rhesus macaque(1)
Tag
  • His Tag(7)
  • His Tag & Avi Tag(3)
  • Fc Tag(1)
  • Fc Tag & Avi Tag(1)
Host
  • HEK293(12)
Conjugate
  • Unconjugated(8)
  • Biotin-labeled(4)
Grade
  • RUO(11)
  • PG (pre-GMP)(1)
Low Endotoxin
  • Yes(3)
  • No(9)
You Have Viewed 1-10 Of 12 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

抗体購入プラットフォーム

プロジェクトステージタイプ由来疾患領域適応症
CD25 mAb - 01PCCMonoclonalHumanized MouseSolid TumorSolid tumor
プロジェクト
CD25 mAb - 01
ステージ
PCC
タイプ
Monoclonal
由来
Humanized Mouse
疾患領域
Solid Tumor
適応症
Solid tumor
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Basiliximab biobetter (Mabtech/Sorrento)STI-003Phase 3 ClinicalTaizhou Maibo Taike Biotechnology Co Ltd
Autoimmune Diseases
詳細
LMB-2LMB-2; LMB-2aPhase 2 ClinicalNational Cancer Institute
Leukemia; Leukemia, Hairy Cell; Leukemia, T-Cell; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Skin Melanoma; Skin Neoplasms
詳細
Nemvaleukin alfaRDB-1419; RDB-1450; ALKS-4230Phase 2 ClinicalAlkermes Plc
Fallopian Tube Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
Camidanlumab tesirineADCT-301Phase 2 ClinicalAdc Therapeutics Sa, Genmab A/S
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Melanoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
詳細
90Y-HAT (NCI)Phase 2 ClinicalNational Cancer Institute
Hodgkin Disease; Lymphoma, Non-Hodgkin
詳細
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Graft vs Host Disease
詳細
90Y BasiliximabPhase 2 ClinicalCity Of Hope National Medical Center
Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
詳細
PT-101PT-101; MK-6194; PT101Phase 1 ClinicalPandion Therapeutics
Colitis, Ulcerative; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Vitiligo
詳細
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1HuMikβ1-1Phase 1 ClinicalF. Hoffmann-La Roche Ltd, National Institutes Of Health
Celiac Disease; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphoid; Paraparesis, Tropical Spastic
詳細
BA-1106TS-1904; BA-1106; RR-102Phase 1 ClinicalShandong Boan Biotechnology Co Ltd
Solid tumours
詳細
XmAb-564XmAb-564; XmAb564; XmAb-27564Phase 1 ClinicalXencor Inc
Autoimmune Diseases; Dermatitis, Atopic; Psoriasis
詳細
PF-08046032PF-08046032Phase 1 ClinicalPfizer Inc
Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck
詳細
IL2 CD25 fusion protein (Bristol-Myers Squibb)Phase 1 ClinicalUniversity Of Miami
Autoimmune Diseases
詳細
9MW-39119MW3911; 9MW-3911Phase 1 ClinicalNanjing Nuo Aixin Biotechnology Co Ltd
Neoplasms
詳細
In 111-DOTA-BasiliximabPhase 1 ClinicalCity Of Hope National Medical Center
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
詳細
BMS-986326BMS-986326Phase 1 ClinicalBristol-Myers Squibb Company
Dermatitis, Atopic; Lupus Vulgaris
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Daclizumab biosimilar (Shanghai CP Guojian)ApprovedSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd健尼哌Mainland ChinaRejection of renal transplantationnull2011-01-12
Rejection of renal transplantation
詳細
DaclizumabR-35; BIIB-019; RO-247375ApprovedAbbvie Inc, Biogen Inc, F. Hoffmann-La Roche LtdZinbryta, ZenapaxUnited StatesRejection of organ transplantationF. Hoffmann-La Roche Ag1997-12-10
Anemia, Aplastic; Anemia, Diamond-Blackfan; Arthritis, Juvenile; Asthma; Behcet Syndrome; Breast Neoplasms; Carcinoma, Ductal; Colitis, Ulcerative; Diabetes Mellitus, Type 1; Gastrointestinal Diseases; Granulomatosis with Polyangiitis; HIV Infections; HTLV-I Infections; Inflammatory Bowel Diseases; Iritis; Leukemia; Leukemia, T-Cell; Lymphoma; Melanoma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myelodysplastic Syndromes; Psoriasis; Radiation Injuries; Red-Cell Aplasia, Pure; Rejection in heart transplantation; Rejection of organ transplantation; Retinal Diseases; Thrombocytopenia; Uveitis; Uveitis, Anterior
詳細
BasiliximabCHT-25; chRFT5; CHI-621; SDZ-CHI-621ApprovedNovartis Pharma Ag舒莱, SimulectUnited StatesRejection of organ transplantationNovartis Pharma Ag1998-05-12
Anemia, Aplastic; Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Emphysema; Hemoglobinuria, Paroxysmal; Hodgkin Disease; Keratoplasty rejection; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Pulmonary Disease, Chronic Obstructive; Rejection of renal transplantation; Rejection of organ transplantation; Uveitis
詳細
Customer Reviews
  • E***n2023-04-08
    Yeast cells expressing and displaying different IL2 variants were incubated 1h in the presence of CD25 protein with His tag (Human Il-2 R alpha Acrobiosystems #ILA-H52H9) at a final concentration of 4µg/ml. Next, cells were washed and incubated with a mouse Anti-His-PE. The yeast cells were washed and were analyzed using FACS. We observed detectable amounts of fluorescence bound to yeast cells displaying specific IL2 variants confirming that CD25 could bind to certain constructs and providing evidence that certain IL2 variants were correctly folded.
  • 1***22022-08-03
    I purchased the company’s mouse-derived CD25 protein for the evaluation of CD25 antibody affinity. It achieved a high sensitivity detection with a small amount! Very satisfied, will come back to purchase more if needed!